| Kathryn A Lilley, MD | |
|
3200 E Racine St, Janesville, WI 53546-2343 | |
| (608) 371-8000 | |
| (608) 371-8939 |
| Full Name | Kathryn A Lilley |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 30 Years |
| Location | 3200 E Racine St, Janesville, Wisconsin |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104872670 | NPI | - | NPPES |
| 1104872670 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0002X | Internal Medicine - Hospice And Palliative Medicine | 41934-020 (Wisconsin) | Secondary |
| 207R00000X | Internal Medicine | 41934-020 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ssm Health At Home Home Health-wisconsin | Madison, WI | Home health agency |
| Transitions Home Health | Elkhorn, WI | Home health agency |
| Agrace Hospicecare | Madison, WI | Hospice |
| Home Health United Hospice | Baraboo, WI | Hospice |
| Ssm Health St Mary's Hospital - Janesville | Janesville, WI | Hospital |
| Ssm Health St Mary's Hospital - Madison | Madison, WI | Hospital |
| Edgerton Hospital And Health Services | Edgerton, WI | Hospital |
| Rock Haven | Janesville, WI | Nursing home |
| Cedar Crest Health Center | Janesville, WI | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dean Health Systems Inc | 7012827983 | 1068 |
News Archive
The future of drug design lies in developing therapies that can target specific cellular processes without causing adverse reactions in other areas of the nervous system. Scientists at the Universities of Bristol and Li-ge in Belgium have discovered how to design drugs to target specific areas of the brain.
There are two main treatments for stroke caused by a clot in a blood vessel in the brain. One treatment, mechanical thrombectomy, involves pulling the clot out with a specialized catheter that is inserted into the artery in the groin and guided by imaging to the clot.
US-Australian drug discovery company, Novogen Limited, in conjunction with Australian paediatric cancer researchers, released key pre-clinical data on experimental cancer drug-candidate, TRXE-009, confirming its potential to become an important new therapy against an incurable paediatric brain cancer called DIPG (diffuse intrinsic pontine glioma).
The incidence of prostate cancer among men of Afro-Caribbean origin is higher than in white men, they are more likely to be diagnosed as emergencies and their mortality rates are higher.
› Verified 8 days ago
| Entity Name | Dean Health Systems Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053358846 PECOS PAC ID: 7012827983 Enrollment ID: O20031105000584 |
News Archive
The future of drug design lies in developing therapies that can target specific cellular processes without causing adverse reactions in other areas of the nervous system. Scientists at the Universities of Bristol and Li-ge in Belgium have discovered how to design drugs to target specific areas of the brain.
There are two main treatments for stroke caused by a clot in a blood vessel in the brain. One treatment, mechanical thrombectomy, involves pulling the clot out with a specialized catheter that is inserted into the artery in the groin and guided by imaging to the clot.
US-Australian drug discovery company, Novogen Limited, in conjunction with Australian paediatric cancer researchers, released key pre-clinical data on experimental cancer drug-candidate, TRXE-009, confirming its potential to become an important new therapy against an incurable paediatric brain cancer called DIPG (diffuse intrinsic pontine glioma).
The incidence of prostate cancer among men of Afro-Caribbean origin is higher than in white men, they are more likely to be diagnosed as emergencies and their mortality rates are higher.
› Verified 8 days ago
| Entity Name | Mercy Health System Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598718603 PECOS PAC ID: 7416860440 Enrollment ID: O20031113000164 |
News Archive
The future of drug design lies in developing therapies that can target specific cellular processes without causing adverse reactions in other areas of the nervous system. Scientists at the Universities of Bristol and Li-ge in Belgium have discovered how to design drugs to target specific areas of the brain.
There are two main treatments for stroke caused by a clot in a blood vessel in the brain. One treatment, mechanical thrombectomy, involves pulling the clot out with a specialized catheter that is inserted into the artery in the groin and guided by imaging to the clot.
US-Australian drug discovery company, Novogen Limited, in conjunction with Australian paediatric cancer researchers, released key pre-clinical data on experimental cancer drug-candidate, TRXE-009, confirming its potential to become an important new therapy against an incurable paediatric brain cancer called DIPG (diffuse intrinsic pontine glioma).
The incidence of prostate cancer among men of Afro-Caribbean origin is higher than in white men, they are more likely to be diagnosed as emergencies and their mortality rates are higher.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kathryn A Lilley, MD 3200 E Racine St, Janesville, WI 53546-2343 Ph: (608) 371-8000 | Kathryn A Lilley, MD 3200 E Racine St, Janesville, WI 53546-2343 Ph: (608) 371-8000 |
News Archive
The future of drug design lies in developing therapies that can target specific cellular processes without causing adverse reactions in other areas of the nervous system. Scientists at the Universities of Bristol and Li-ge in Belgium have discovered how to design drugs to target specific areas of the brain.
There are two main treatments for stroke caused by a clot in a blood vessel in the brain. One treatment, mechanical thrombectomy, involves pulling the clot out with a specialized catheter that is inserted into the artery in the groin and guided by imaging to the clot.
US-Australian drug discovery company, Novogen Limited, in conjunction with Australian paediatric cancer researchers, released key pre-clinical data on experimental cancer drug-candidate, TRXE-009, confirming its potential to become an important new therapy against an incurable paediatric brain cancer called DIPG (diffuse intrinsic pontine glioma).
The incidence of prostate cancer among men of Afro-Caribbean origin is higher than in white men, they are more likely to be diagnosed as emergencies and their mortality rates are higher.
› Verified 8 days ago
Imdad Ahmed, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 Mineral Point Ave, Janesville, WI 53548 Phone: 608-756-6868 Fax: 608-756-6289 | |
Jacob A Thomas, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 Mineral Point Ave, Janesville, WI 53548 Phone: 608-756-6741 Fax: 608-756-6376 | |
David R. Isaacson, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 Mineral Point Ave, Janesville, WI 53548 Phone: 608-756-6261 Fax: 068-756-6236 | |
Dr. Fahim Haider Jafary, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 Mineral Point Ave, Janesville, WI 53548 Phone: 608-756-6868 | |
Kauseruzzaman A. Khan, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3524 E Milwaukee St, Janesville, WI 53546 Phone: 608-756-7100 Fax: 608-741-4700 | |
William N Brandt, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 3200 E Racine St, Janesville, WI 53546 Phone: 608-371-8000 Fax: 608-371-8277 |